Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study

The glucagon-like peptide-1 receptor agonist family together with the renal sodium/glucose cotransporter-2 inhibitors have garnered interest as potential therapeutic agents for subjects with type 2 diabetes and obesity. In these patients, bariatric surgery is indicated based in a BMI ≥ 35 kg/m(2). A...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Cano, Carolina, Santos, Maria Dolores, Sánchez, Enric, Martí, Raquel, Bueno, Marta, Gutiérrez-Carrasquilla, Liliana, Lecube, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881618/
https://www.ncbi.nlm.nih.gov/pubmed/35217772
http://dx.doi.org/10.1038/s41598-022-07250-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881618/
https://www.ncbi.nlm.nih.gov/pubmed/35217772
http://dx.doi.org/10.1038/s41598-022-07250-z

Ejemplares similares